Boston One Step Liquid Enzymatic Cleaner

K200416 · Bausch & Lomb, Incorporated · MRC · Sep 23, 2020 · Ophthalmic

Device Facts

• Record ID: K200416
• Device Name: Boston One Step Liquid Enzymatic Cleaner
• Applicant: Bausch & Lomb, Incorporated
• Product Code: MRC · Ophthalmic
• Decision Date: Sep 23, 2020
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 886.5918
• Device Class: Class 2

Intended Use

Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner is indicated for weekly enzymatic cleaning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses during conditioning (wetting, soaking, and disinfecting) with Boston Conditioning Solution or Boston ADVANCE Comfort Formula Conditioning Solution.

Device Story

Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner is a preservative-free, sterile, aqueous solution containing subtilisin (proteolytic enzyme) and glycerol. Used by contact lens wearers for weekly enzymatic cleaning of rigid gas permeable (RGP) lenses. The solution is added during the conditioning (wetting, soaking, and disinfecting) process using compatible Boston conditioning solutions. The device removes protein deposits from lens surfaces, maintaining lens clarity and comfort. The product is provided in single-use dispensers (SUD).

Clinical Evidence

Bench testing only. Biocompatibility, cytotoxicity, and ocular irritation studies were performed on the cleaner and primary packaging components. Systemic toxicity testing was conducted on packaging components. Results demonstrated biocompatibility and performance equivalent to the predicate.

Technological Characteristics

Preservative-free aqueous solution containing subtilisin and glycerol. Packaged in single-use dispensers (SUD). No changes to product formulation or specifications. Biocompatibility verified per FDA guidance for contact lens care products.

Indications for Use

Indicated for weekly enzymatic cleaning of fluorosilicone acrylate and silicone acrylate rigid gas permeable contact lenses for users of Boston Conditioning Solution or Boston ADVANCE Comfort Formula Conditioning Solution.

Regulatory Classification

Identification

A rigid gas permeable contact lens care product is a device intended for use in the cleaning, conditioning, rinsing, lubricating/rewetting, or storing of a rigid gas permeable contact lens. This includes all solutions and tablets used together with rigid gas permeable contact lenses.

Special Controls

*Classification.* Class II (Special Controls) Guidance Document: “Guidance for Industry Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products.”

Predicate Devices

• Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner (K181627)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

September 23, 2020

Bausch & Lomb Incorporated Pinal Shah Manager Regulatory Affairs 400 Somerset Corporate Boulevard Bridgewater, NJ 08807

## Re: K200416

Trade/Device Name: Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner Regulation Number: 21 CFR 886.5918 Regulation Name: Rigid Gas Permeable Contact Lens Care Products Regulatory Class: Class II Product Code: MRC Dated: August 20, 2020 Received: August 21, 2020

# Dear Pinal Shah:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see

{1}------------------------------------------------

https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

J. Angelo Green, Ph.D. Assistant Director DHT1A: Division of Ophthalmic Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K200416

Device Name

Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner

Indications for Use (Describe)

Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner is indicated for weekly enzymatic cleaning of fluorosilicone acrylate and silicone acrylate rigid gas permeable contact lenses during (wetting, soaking, and disinfecting) with Boston Conditioning Solution or Boston ADVANCE Comfort Formula Conditioning Solution.

| Type of Use (Select one or both, as applicable) | |
|-------------------------------------------------|--|
|-------------------------------------------------|--|

Prescription Use (Part 21 CFR 801 Subpart D)

|X Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(k) SUMMARY

## Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner

#### Submitter Information 1.

| Primary | Alternate |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pinal Shah<br>Manager, Regulatory Affairs<br>400 Somerset Corporate Boulevard<br>Bridgewater, New Jersey 08807<br>Tel: [phone]<br>Fax: [phone]<br>Email: [e-mail] | Susan Pate<br>Sr Manager Regulatory Affairs<br>1400 North Goodman Street<br>Rochester, NY 14609<br>Tel. [phone]<br>Email: [e-mail] |

#### Summary Prepared: February 18, 2020

#### 2. Device Name

| Trade Name: | Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner |
|------------------------|--------------------------------------------------------|
| Classification: | Products, Contact Lens Care, Rigid Gas Permeable |
| Device classification: | Class II |
| Regulation Number: | 886.5918 Rigid Gas Permeable Contact Lens Care Product |
| Product Code: | MRC |

#### 3. Predicate Device

Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner (K181627).

#### 4. Description of the Device

Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner is a preservative free sterile, aqueous solution containing proteolytic enzyme (subtilisin) as the active ingredient, and glycerol.

#### ട്. Intended Use

Bausch + Lomb Boston One Step Liquid Enzymatic Cleaner is indicated for weekly enzymatic cleaning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses during conditioning (wetting, soaking, and disinfecting) with Boston Conditioning Solution or Boston ADVANCE Comfort Formula Conditioning Solution.

{4}------------------------------------------------

#### 6. Description of Safety and Substantial Equivalence

Bausch + Lomb submitted this 510(k) to add an alternative manufacturing site located at Unither Pharmaceuticals in Coutances, France for Boston One Step Liquid Enzymatic Cleaner packaged as a Single-Use Dispenser (SUD). Preclinical testing was completed to support the additional manufacturing site change, in addition to changing the SUD packaging resin, and raw material supplier sources. There are not any changes to the product formulation, specifications or care regimen.

Preclinical testing was completed as described in Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products, May 1, 1997. A brief summary of the test results is provided below:

### Biocompatibility

Cytotoxicity and ocular irritation studies were completed for the Boston One Step Liquid Enzymatic Cleaner and its primary packaging components. Systemic toxicity was conducted on the primary packaging components. The test results demonstrated the biocompatibility of the Boston One Step Liquid Enzymatic Cleaner and its primary packaging components.

#### 7. Substantial Equivalence

The preclinical testing results demonstrate that the safety, effectiveness and performance of Boston One Step Liquid Enzymatic Cleaner are substantially equivalent to the currently commercialized Boston One Step Liquid Enzymatic Cleaner.